PharMerica (NYSE: PMC) reported earnings on May 2. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended March 31 (Q1), PharMerica beat slightly on revenue and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue contracted and GAAP earnings per share increased significantly.

Margins grew across the board.

Revenue details
PharMerica logged revenue of $498.9 million. The seven analysts polled by S&P Capital IQ expected net sales of $493.6 million on the same basis. GAAP reported sales were 6.8% lower than the prior-year quarter's $535.1 million.

My

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $0.30. The eight earnings estimates compiled by S&P Capital IQ predicted $0.27 per share. GAAP EPS of $0.19 for Q1 were 73% higher than the prior-year quarter's $0.11 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 14.6%, 250 basis points better than the prior-year quarter. Operating margin was 3.5%, 140 basis points better than the prior-year quarter. Net margin was 1.1%, 50 basis points better than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $488.5 million. On the bottom line, the average EPS estimate is $0.31.

Next year's average estimate for revenue is $1.94 billion. The average EPS estimate is $1.20.

Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 125 members out of 131 rating the stock outperform, and six members rating it underperform. Among 24 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 23 give PharMerica a green thumbs-up, and one gives it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on PharMerica is outperform, with an average price target of $15.25.

The healthcare investing landscape is littered with also-rans and a few major winners. Is PharMerica prepared for the future? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will deliver amazing returns during the next few years. Click here for instant access to this free report.

Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.